Ashwani Sharma

Title: Ashwani Sharma: Research on Targeting Protozoan Tubulin

Introduction

Ashwani Sharma is an inventor based in Brugg, Switzerland, associated with the Paul Scherrer Institut. His patent work concerns a potential strategy for inhibiting protozoan replication by targeting parasite tubulin.

Latest Patents

The supplied information lists one patent for Sharma: “Use of parabulin for targeting protozoan tubulin for the inhibition of protozoan replication.” The invention describes apicomplexan tubulin as a potential drug target and proposes using parabulin, or its derivatives, to destabilize parasite microtubules while avoiding harm to the mammalian host. The proposed approach aims to interfere with essential parasite processes, including replication and host-cell invasion, and may offer a strategy for addressing drug resistance.

The patent identifies parabulin as having a molecular weight of 373.4 Da and gives its chemical name as 3-(3,4-dimethoxyphenyl)-N-[(3,4,5-trimethoxyphenyl)methyl]prop-2-enamide. The supplied molecular formula and SMILES notation appear incomplete or malformed, so they are not reproduced here. Sharma’s listed portfolio comprises 1 patent.

Career Highlights

A key highlight in Sharma’s listed patent activity is the proposed selective targeting of parasite microtubules. The invention focuses on distinguishing protozoan tubulin from its mammalian counterpart, with the goal of inhibiting parasite activity while limiting effects on the host.

Collaborations

Sharma is associated with the Paul Scherrer Institut. Natacha Gaillard and Michel Steinmetz are identified in the supplied information as his coworkers.

Conclusion

Ashwani Sharma’s listed patent presents parabulin-based targeting of protozoan tubulin as a potential approach to inhibiting parasite replication and host-cell invasion.